Objectif The main objective of the CellUp business innovation project is to develop and commercialize the new disruptive in-lineanalytics sensor for upstream cell culture process that the biopharmaceutical industry needs for the quality and processcontrol during the phases of process development, scale-up and manufacturing of vaccines and antibodies for humanmedicines based on eukaryote cells culture.This new bioprocess analyser will be the first industrial sensor able to perform in-line quantification of the main nutrients andmetabolites during the mammalian cell culture inside the bioreactor.Today, cell cultures in bioreactors are only monitored in real time with temperature, PH and Oxygen density sensors. Thenegative consequences of such a limited control are huge in terms of batch failures, time consumed at each scale-up phaseand in terms of untapped production yield improvement.Our company, with its unique integrated SWIFTS technology has the opportunity to fix the above described problem byoffering a high performance miniaturized in-line Raman analyzer which can be implemented as an industrial GMP sensor.Based on the needs expressed by several major industrial actors, the company has already developed a first productsuccessfully evaluated and released end of 2016 under the name ProCellics.The objective of the CellUp project is to go a step further in the integration of the Raman analyser thanks to a newconfiguration of our technology, called SWITS-CD. We will also develop a new “standard addition method” technology and arelated software to provide an easy and robust way to implement the monitoring of the cell culture. The key to the success ofthis new methodology development is a cell culture activity carried internally by our company.The total accessible market is estimated at 750 M€ for a first equipment of the 20,000 biopharma industry bioreactors, allowing the emergence of a European leader with more than 300 job creation over 10 years. Champ scientifique natural sciencescomputer and information sciencessoftwareengineering and technologyenvironmental biotechnologybioremediationbioreactorssocial sciencessociologyindustrial relationsautomationengineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensorsnatural sciencesphysical sciencesopticsspectroscopy Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Thème(s) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Appel à propositions H2020-SMEInst-2016-2017 Voir d’autres projets de cet appel Sous appel H2020-SMEINST-2-2016-2017 Régime de financement SME-2 - SME instrument phase 2 Coordinateur RESOLUTION SPECTRA SYSTEMS Contribution nette de l'UE € 1 969 553,75 Adresse 13 CHEMIN DU VIEUX CHENE 38240 MEYLAN France Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région Auvergne-Rhône-Alpes Rhône-Alpes Isère Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 1 969 553,75
